Literature DB >> 216556

VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.

M K Samson, L H Baker, R W Talley, R J Fraile.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 216556     DOI： 10.1016/0014-2964(78)90124-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  7 in total

1.  Phase II study of teniposide in adenocarcinoma of the lung.

Authors:  J B Sørensen; F Bach; P Dombernowsky; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 3.  VM26: phase I and II studies.

Authors:  F R Macbeth
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Teniposide: overview of its therapeutic potential in adult cancers.

Authors:  F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.